Price
Financials
Standalone, Rs crore| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 23 | 17 | 21 | 24 |
| Expenses | 14 | 15 | 17 | 15 |
| Operating Profit | 9 | 3 | 4 | 9 |
| OPM % | 38% | 16% | 19% | 37% |
| Other Income | 0 | 1 | 1 | 2 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 9 | 3 | 5 | 10 |
| Tax % | 26% | -34% | 26% | 25% |
| Net Profit | 7 | 4 | 4 | 8 |
| EPS in Rs | 4.18 | 2.10 | 1.93 | 3.77 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 17 | 26 | 28 | 42 | 37 | 43 |
| Expenses | 18 | 22 | 24 | 25 | 26 | 30 |
| Operating Profit | -1 | 4 | 4 | 17 | 12 | 13 |
| OPM % | -6% | 14% | 15% | 40% | 31% | 30% |
| Other Income | 0 | -0 | 0 | 0 | 1 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | -1 | 3 | 4 | 17 | 12 | 15 |
| Tax % | -3% | 23% | 25% | 25% | 10% | 26% |
| Net Profit | -1 | 3 | 3 | 12 | 11 | 11 |
| EPS in Rs | -333.33 | 856.67 | 1,036.67 | 2,500.00 | 5.36 | 5.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 9% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 20% | 15% | 16% | ||
| Compounded Profit Growth | % | 68% | 54% | 7% | ||
| Stock Price CAGR | % | % | % | -22% | ||
| Return on Equity | % | 31% | 27% | 15% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.05 | 20 | 20 |
| Reserves | -1 | 1 | 5 | 17 | 49 | 61 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 9 | 5 | 8 | 2 | 2 | 6 |
| Total Liabilities | 8 | 7 | 12 | 19 | 71 | 87 |
| Fixed Assets | 1 | 0 | 1 | 1 | 1 | 1 |
| CWIP | 0 | 0 | 0 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 3 |
| Other Assets | 7 | 6 | 12 | 18 | 70 | 83 |
| Total Assets | 8 | 7 | 12 | 19 | 71 | 87 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 3 | 5 | -3 | 6 | 8 |
| Cash from Investing Activity | -1 | -0 | -1 | -1 | -46 | 6 |
| Cash from Financing Activity | 0 | 0 | -0 | -0 | 41 | -0 |
| Net Cash Flow | -1 | 3 | 3 | -4 | 1 | 14 |
| Free Cash Flow | -1 | 3 | 4 | -4 | 5 | 7 |
| CFO/OP | -26% | 108% | 135% | 6% | 62% | 88% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 93 | 12 | 16 | 114 | 163 | 177 |
| Inventory Days | 66 | |||||
| Days Payable | 39 | |||||
| Cash Conversion Cycle | 93 | 12 | 16 | 141 | 163 | 177 |
| Working Capital Days | -45 | -25 | -38 | 111 | 166 | 158 |
| ROCE % | 1,069% | 133% | 153% | 28% | 21% |
| Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Promoters | 70.65% | 70.65% | 70.65% |
| FIIs | 1.16% | 1.16% | 0.00% |
| Public | 28.19% | 28.20% | 29.35% |
| No. of Shareholders | 1,374 | 1,606 | 1,483 |
Fundamentals
Market Cap₹ 88.0 Cr.
Current Price₹ 44.0
Stock P/E7.70
Book Value₹ 40.3
ROCE20.5 %
ROE15.3 %
Dividend Yield1.14 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)16%
Compounded Profit Growth (TTM)7%
Standalone figures.
Valuation
Market capRs 86 Cr
Enterprise valueRs 84 Cr
P/E (TTM)33.47x
Price to book57.73x
Price to sales3.28x
EV / EBITDA22.88x
EV / EBIT25.14x
EV / sales3.20x
Price to cash flow28.48x
Earnings yield2.99%
Profitability
Operating margin (excl. other income)14.31%
Operating margin (incl. other income)13.97%
EBITDA margin13.97%
Pre-tax margin12.71%
Net profit margin9.81%
ROE1285.00%
ROCE1040.62%
ROA34.57%
Tax rate22.82%
Other income / net worth-6.04%
Growth
Sales growth (latest year)52.06%
Per share
EPS (TTM)Rs 1.28
EPS (latest year)Rs 856.67
Book value per shareRs 0.74
Sales per shareRs 13.10
Cash flow per shareRs 1.51
Free cash flow per shareRs 3.50
Efficiency
Asset turnover3.98x
Fixed asset turnover59.55x
Inventory turnover4.27x
Inventory days85 days
Debtor days12 days
Debtors turnover29.77x
Creditor days39 days
Cash conversion cycle177 days
Working capital days158 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 2 Cr
Net debtRs -2 Cr
Debt to equity0.08x
Net debt / EBITDA-0.63x
Owners' fund to total sources22.64%
Debt to assets1.82%
Cash flow
Cash from Operating Activity (latest year)Rs 3 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs 3 Cr
Free cash flow (latest year)Rs 7 Cr
FCFE (approx.: FCF + change in debt)Rs 7 Cr
Cash from ops / profit, 5 years0.47x
Sales to cash flow8.68x
Statement figures
Net sales (TTM)Rs 26 Cr
Net sales (latest year)Rs 26 Cr
Operating profit excl. other income (latest year)Rs 4 Cr
Other income (TTM)Rs -0 Cr
EBITDA (TTM)Rs 4 Cr
PBDT (TTM)Rs 4 Cr
Profit before tax (TTM)Rs 3 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 3 Cr
Net profit (latest year)Rs 3 Cr
Depreciation (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 9 Cr
Total expenditure (latest year)Rs 22 Cr
Total income (latest year)Rs 26 Cr
Share capitalRs 0 Cr
ReservesRs 1 Cr
Shareholders' fundsRs 1 Cr
Total assetsRs 7 Cr
Net blockRs 0 Cr
ReceivablesRs 1 Cr
InventoryRs 2 Cr
Other liabilitiesRs 5 Cr
Shares outstanding (crore)2.00
Ownership
Promoter holding70.65%
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 544353 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +1.2% | -2.8% | +4.0 pts |
| 1 month | -1.1% | -6.8% | +5.6 pts |
| 3 months | +0.8% | -7.6% | +8.4 pts |
Red flags
F-score 7 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Amwill Health Care Ltd?
Amwill Health Care Ltd (544353) has a market capitalisation of Rs 88.0 Cr. at the 2026-10-01 close.
What is the P/E ratio of Amwill Health Care Ltd?
Amwill Health Care Ltd trades at a P/E of 7.70 on trailing twelve-month profit, at the 2026-10-01 close.